Alterations of RNA Metabolism by Proteomic Analysis of Breast Cancer Cells Exposed to Marycin: A New Optically Active Porphyrin.


Journal

Current molecular pharmacology
ISSN: 1874-4702
Titre abrégé: Curr Mol Pharmacol
Pays: United Arab Emirates
ID NLM: 101467997

Informations de publication

Date de publication:
2019
Historique:
received: 05 05 2018
revised: 11 01 2019
accepted: 22 01 2019
pubmed: 5 2 2019
medline: 17 8 2019
entrez: 5 2 2019
Statut: ppublish

Résumé

Marycin is a porphyrin-type compound synthetically modified to spontaneously release fluorescence. This study is aimed at understanding possible mechanisms that could account for the antiproliferative effects observed in marycin. A proteomic approach was used to identify molecular effects. The proteome of proliferating MDA-MB-231 breast cancer cells was compared with that of marycin-treated cells. Label-free proteomic analysis by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was used to reveal changes in protein expression and fluorescence microscopy and flow cytometry were used to detect subcellular organelle dysfunctions. The bioinformatic analysis indicated an enhancement of the expression of proteins remodeling RNA splicing and more in general, of RNA metabolism. Marycin did not localize into the mitochondria and did not produce a dramatic increase of ROS levels in MDA-MB-231 cells. Marycin stained organelles probably peroxisomes. The results could support the possibility that the peroxisomes are involved in cell response to marycin.

Identifiants

pubmed: 30714537
pii: CMP-EPUB-96320
doi: 10.2174/1874467212666190204102112
doi:

Substances chimiques

Hematoporphyrins 0
Porphyrins 0
Reactive Oxygen Species 0
marycin 111775-32-7
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

147-159

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Elena Taverna (E)

Molecular Mechanism Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Maida De Bortoli (M)

Molecular Mechanism Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Elisa Maffioli (E)

Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Cristina Corno (C)

Center for Nano Science and Technology at Polimi, Istituto Italiano di Tecnologia, Fondazione Filarete, Milan, Italy.

Emilio Ciusani (E)

Center for Nano Science and Technology at Polimi, Istituto Italiano di Tecnologia, Fondazione Filarete, Milan, Italy.

Silvio Trivulzio (S)

Laboratory of Clinical Pathology and Medical Genetics, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.

Arnaldo Pinelli (A)

Laboratory of Clinical Pathology and Medical Genetics, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.

Gabriella Tedeschi (G)

Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Research Unit "Iraklis Galatoulas"-Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.

Paola Perego (P)

Dipartimento di Medicina Veterinaria (DiMeVet), University of Milan, Milan, Italy.

Italia Bongarzone (I)

Molecular Mechanism Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH